Research programme: sublingual calcitonin - Albireo Pharma

Drug Profile

Research programme: sublingual calcitonin - Albireo Pharma

Alternative Names: VIAcal

Latest Information Update: 13 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biodel
  • Class Neuropeptides; Peptide hormones
  • Mechanism of Action Bone resorption factor inhibitors; Calcitonin receptor agonists; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Osteoporosis

Most Recent Events

  • 31 Dec 2008 Development discontinued for Osteoporosis before 2009
  • 13 Jul 2007 Preclinical trials in Osteoporosis in USA (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top